Sulfated Polysaccharides from Macroalgae Are Potent Dual Inhibitors of Human ATP-Hydrolyzing Ectonucleotidases NPP1 and CD39.
Adenosine Triphosphate
/ antagonists & inhibitors
Apyrase
/ antagonists & inhibitors
Cell Line, Tumor
Dose-Response Relationship, Drug
Humans
Hydrolysis
/ drug effects
Phosphoric Diester Hydrolases
/ metabolism
Polysaccharides
/ chemistry
Pyrophosphatases
/ antagonists & inhibitors
Seaweed
/ chemistry
Sulfuric Acid Esters
/ chemistry
CD39
NPP1
NTPDase1
adenosine
ectonucleotidase inhibitors
fucoidan
immuno-oncology
macroalgae constituents
sulfated polysaccharides
Journal
Marine drugs
ISSN: 1660-3397
Titre abrégé: Mar Drugs
Pays: Switzerland
ID NLM: 101213729
Informations de publication
Date de publication:
22 Jan 2021
22 Jan 2021
Historique:
received:
29
12
2020
revised:
14
01
2021
accepted:
15
01
2021
entrez:
27
1
2021
pubmed:
28
1
2021
medline:
21
5
2021
Statut:
epublish
Résumé
Extracellular ATP mediates proinflammatory and antiproliferative effects via activation of P2 nucleotide receptors. In contrast, its metabolite, the nucleoside adenosine, is strongly immunosuppressive and enhances tumor proliferation and metastasis. The conversion of ATP to adenosine is catalyzed by ectonucleotidases, which are expressed on immune cells and typically upregulated on tumor cells. In the present study, we identified sulfopolysaccharides from brown and red sea algae to act as potent dual inhibitors of the main ATP-hydrolyzing ectoenzymes, ectonucleotide pyrophosphatase/phosphodiesterase-1 (NPP1) and ecto-nucleoside triphosphate diphosphohydrolase-1 (NTPDase1, CD39), showing nano- to picomolar potency and displaying a non-competitive mechanism of inhibition. We showed that one of the sulfopolysaccharides tested as a representative example reduced adenosine formation at the surface of the human glioblastoma cell line U87 in a concentration-dependent manner. These natural products represent the most potent inhibitors of extracellular ATP hydrolysis known to date and have potential as novel therapeutics for the immunotherapy of cancer.
Identifiants
pubmed: 33499103
pii: md19020051
doi: 10.3390/md19020051
pmc: PMC7911304
pii:
doi:
Substances chimiques
Polysaccharides
0
Sulfuric Acid Esters
0
Adenosine Triphosphate
8L70Q75FXE
Phosphoric Diester Hydrolases
EC 3.1.4.-
ectonucleotide pyrophosphatase phosphodiesterase 1
EC 3.1.4.1
Pyrophosphatases
EC 3.6.1.-
Apyrase
EC 3.6.1.5
ENTPD1 protein, human
EC 3.6.1.5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Bundesministerium für Bildung und Forschung
ID : BIGS DrugS
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB1328, Project-ID: 335447717
Organisme : Natural Sciences and Engineering Research Council of Canada
ID : RGPIN-2016-05867
Références
Anal Biochem. 1999 Jun 15;271(1):29-35
pubmed: 10361001
Br J Pharmacol. 2007 Sep;152(1):141-50
pubmed: 17603550
Cell Death Differ. 2014 Jun;21(6):929-40
pubmed: 24531536
Electrophoresis. 2008 Sep;29(17):3685-93
pubmed: 18803183
J Med Chem. 2019 Apr 11;62(7):3677-3695
pubmed: 30895781
Biochim Biophys Acta Gen Subj. 2017 Mar;1861(3):603-614
pubmed: 28011303
Nat Commun. 2018 Oct 24;9(1):4424
pubmed: 30356045
Oncoimmunology. 2016 Jul 11;5(8):e1208875
pubmed: 27622077
FEBS J. 2017 Nov;284(21):3718-3726
pubmed: 28898552
Front Pharmacol. 2018 Jun 14;9:627
pubmed: 29962948
J Neurochem. 2014 Nov;131(3):290-302
pubmed: 24947519
Cancer Cell Int. 2020 May 7;20:154
pubmed: 32410882
Mar Drugs. 2018 May 15;16(5):
pubmed: 29762545
Am J Physiol Cell Physiol. 2020 May 1;318(5):C832-C835
pubmed: 32159362
FEBS J. 2018 Jul;285(13):2481-2494
pubmed: 29717535
Purinergic Signal. 2012 Sep;8(3):437-502
pubmed: 22555564
Mar Drugs. 2019 Jul 26;17(8):
pubmed: 31357497
Anal Biochem. 2020 Aug 15;603:113774
pubmed: 32445636
Anal Biochem. 2014 Feb 1;446:53-8
pubmed: 24144488
Br J Pharmacol. 1995 Jan;114(2):475-81
pubmed: 7533620
Pharmacol Rev. 2006 Sep;58(3):281-341
pubmed: 16968944
Nutr Cancer. 2020 Dec 26;:1-13
pubmed: 33356601
Mar Drugs. 2020 Jun 05;18(6):
pubmed: 32517092
Front Pharmacol. 2017 Feb 15;8:54
pubmed: 28261095
Biochem Pharmacol. 2015 Jan 15;93(2):171-81
pubmed: 25449596
Mar Drugs. 2019 Jan 07;17(1):
pubmed: 30621045
Front Pharmacol. 2020 Sep 08;11:1294
pubmed: 33013365
Int J Biol Macromol. 2020 Jan 15;143:968-976
pubmed: 31726164
Carbohydr Polym. 2020 Jul 1;239:116131
pubmed: 32414455
ACS Biomater Sci Eng. 2019 Mar 11;5(3):1200-1214
pubmed: 33405640
Bioorg Med Chem Lett. 2006 Dec 1;16(23):5943-7
pubmed: 16997558
Inflamm Regen. 2017 Jul 17;37:13
pubmed: 29259712
Purinergic Signal. 2005 Jun;1(2):193-204
pubmed: 18404504
Purinergic Signal. 2009 Mar;5(1):91-106
pubmed: 18528783
Pharmacol Rev. 2011 Sep;63(3):641-83
pubmed: 21737531
Blood. 2012 Jul 19;120(3):511-8
pubmed: 22661701
Mar Drugs. 2020 Apr 08;18(4):
pubmed: 32276359
Pharmacol Rev. 2019 Jul;71(3):345-382
pubmed: 31235653
Neuro Oncol. 2013 Sep;15(9):1160-72
pubmed: 23737488
J Biol Chem. 2014 Feb 7;289(6):3294-306
pubmed: 24338010
Cell Mol Neurobiol. 2003 Jun;23(3):349-64
pubmed: 12825832
Stem Cells Transl Med. 2018 Jun;7(6):477-486
pubmed: 29589874
Purinergic Signal. 2005 Dec;1(4):349-58
pubmed: 18404519
Biomacromolecules. 2009 Nov 9;10(11):2998-3008
pubmed: 19795906
Mar Drugs. 2014 Dec 26;13(1):76-101
pubmed: 25548975
Minn Med. 2000 May;83(5):45-8
pubmed: 10832315
Medchemcomm. 2017 Feb 9;8(5):823-840
pubmed: 30108800
Molecules. 2019 Nov 19;24(22):
pubmed: 31752288
Clin Neurol Neurosurg. 2011 Apr;113(3):224-9
pubmed: 21195542
Cell Tissue Res. 2002 Dec;310(3):257-70
pubmed: 12457224
J Chromatogr A. 2002 Apr 5;952(1-2):275-81
pubmed: 12064539
Anal Biochem. 1991 Aug 15;197(1):157-62
pubmed: 1952059
Immunol Rev. 2017 Mar;276(1):121-144
pubmed: 28258700